Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
J&J Veteran To Continue Rebuilding In 2023
Executive Summary
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
You may also be interested in...
Galapagos Loses Potential Ticket To America As Crohns Trial Flops
The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.
Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
Toledo Data Fail To Give Galapagos A Lift
Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.